CheckMate 025随机3期研究:纳武利尤单抗对比依维莫司治疗晚期肾细胞癌按关键基线因素和既往治疗的结果
CheckMate 025是一项随机3期研究,比较纳武利尤单抗(n=410)与依维莫司(n=411)在既往治疗过的晚期肾细胞癌成人中的疗效。按基线因素分组的亚组分析显示,纳武利尤单抗在多个亚组中均改善总生存期和客观缓解率,包括MSKCC和IMDC风险组、年龄、转移部位、既往治疗等,且3-4级治疗相关不良事件发生率更低。
要点
- 纳武利尤单抗在多个基线亚组中均显示总生存期获益,MSKCC预后不良组HR 0.48(95%CI 0.32-0.70)。
- 所有亚组12个月死亡率纳武利尤单抗均低于依维莫司,客观缓解率也倾向纳武利尤单抗。
- 各亚组3或4级治疗相关不良事件发生率纳武利尤单抗低于依维莫司。
核心结论
- 纳武利尤单抗在多个亚组中总生存期和客观缓解率获益的趋势,且无显著安全性担忧,可能有助于指导治疗决策,并进一步支持纳武利尤单抗作为既往治疗过的晚期肾细胞癌患者的标准治疗。
研究设计与样本
- 随机3期CheckMate 025研究,纳武利尤单抗组n=410,依维莫司组n=411,既往治疗过的晚期肾细胞癌成人(75%男性;88%白人)。
- 亚组总生存期分析采用Kaplan-Meier法,风险比采用Cox比例风险模型估计。
- 干预:纳武利尤单抗3mg/kg每2周一次或依维莫司10mg每日一次。
- 最低随访14个月。
主要发现
- 纳武利尤单抗在多个亚组中均显示总生存期改善,包括MSKCC和IMDC风险组、年龄<65和≥65岁、1个和2个及以上转移部位、骨/肝/肺转移、既往治疗线数、既往治疗持续时间以及既往舒尼替尼、帕唑帕尼或白细胞介素-2治疗。
- MSKCC预后不良患者中纳武利尤单抗对比依维莫司的获益显著,风险比0.48(95%CI 0.32-0.70)。
- 所有亚组12个月死亡率纳武利尤单抗低于依维莫司。
- 客观缓解率也倾向纳武利尤单抗。
- 各亚组3或4级治疗相关不良事件发生率纳武利尤单抗低于依维莫司。
关键数值与推荐
- MSKCC预后不良组:纳武利尤单抗对比依维莫司的总生存期风险比0.48(95%CI 0.32-0.70)。
临床怎么用
- 原文结论指出纳武利尤单抗在多个亚组中总生存期和客观缓解率获益的趋势可能有助于指导治疗决策,并进一步支持纳武利尤单抗作为既往治疗过的晚期肾细胞癌患者的标准治疗。
局限性
- 局限性包括事后分析和组间样本量不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The randomized, phase 3 CheckMate 025 study of nivolumab (n=410) versus everolimus (n=411) in previously treated adults (75% male; 88% white) with advanced renal cell carcinoma (aRCC) demonstrated significantly improved overall survival (OS) and objective response rate (ORR). OBJECTIVE: To investigate which baseline factors were associated with OS and ORR benefit with nivolumab versus everolimus. DESIGN, SETTING, AND PARTICIPANTS: Subgroup OS analyses were performed using Kaplan-Meier methodology. Hazard ratios were estimated using the Cox proportional hazards model. INTERVENTION: Nivolumab 3mg/kg every 2 wk or everolimus 10mg once daily. RESULTS AND LIMITATIONS: The minimum follow-up was 14 mo. Baseline subgroup distributions were balanced between nivolumab and everolimus arms. Nivolumab demonstrated an OS improvement versus everolimus across subgroups, including Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium risk groups; age <65 and ≥65 yr; one and two or more sites of metastases; bone, liver, and lung metastases; number of prior therapies; duration of prior therapy; and prior sunitinib, pazopanib, or interleukin-2 therapy. The benefit with nivolumab versus everolimus was noteworthy for patients with poor MSKCC risk (hazard ratio 0.48, 95% confidence interval 0.32-0.70). The mortality rate at 12 mo for all subgroups was lower with nivolumab compared with everolimus. ORR also favored nivolumab. The incidence of grade 3 or 4 treatment-related adverse events across subgroups was lower with nivolumab. Limitations include the post hoc analysis and differing sample sizes between groups. CONCLUSION: The trend for OS and ORR benefit with nivolumab for multiple subgroups, without notable safety concerns, may help to guide treatment decisions, and further supports nivolumab as the standard of care in previously treated patients with aRCC. PATIENT SUMMARY: We investigated the impact of demographic and pretreatment features on survival benefit and tumor response with nivolumab versus everolimus in advanced renal cell carcinoma (aRCC). Survival benefit and response were observed for multiple subgroups, supporting the use of nivolumab as a new standard of care across a broad range of patients with previously treated aRCC. The trial is registered on ClinicalTrials.gov as NCT01668784.
引用
- Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol. 2017. PMID: 28262413. doi:10.1016/j.eururo.2017.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。